A Global, Interventional, Open-label Trial of T-DXd-based Therapy Followed by Palbociclib, Endocrine Therapy and Dual HER2 Blockade in First-line HER2+/ HR+ Advanced or Metastatic Breast Cancer and Retreatment With T-DXd (DB-Guide)

This study will evaluate a structured sequential treatment strategy starting with T-DXd + pertuzumab upfront therapy, followed by an optimized maintenance therapy with dual HER2+blockade + CDK4/6i + ET and the opportunity to retreat with T-DXd once patients progress under maintenance aimed to maximizing disease control, optimizing tolerability, and preserving T-DXd as a future therapeutic option, while ensuring participant safety and regulatory compliance in participants with HER2+/HR+ advanced/metastatic breast cancer.

开始日期2026-09-04

申办/合作机构

Daiichi Sankyo Co., Ltd.

[+1]

NCT07748208

/ Not yet recruiting临床2期

A Phase II Prospective, Open-Label Safety Study of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With PIK3CA-Mutated Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer and Type 2 Diabetes

This study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.

开始日期2026-09-01

申办/合作机构

Hoffmann-La Roche Ltd.

ChiCTR2600129847

/ Not yet recruiting临床2期IIT

Becotatug Vedotin combined with Palbociclib for advanced head and neck squamous cell carcinoma after failure of first-line treatment: a single-arm, single-center phase II exploratory study

开始日期2026-09-01

申办/合作机构

上海交通大学医学院附属第九人民医院

100 项与哌柏西利相关的临床结果

登录后查看更多信息

100 项与哌柏西利相关的转化医学

登录后查看更多信息

100 项与哌柏西利相关的专利（医药）

登录后查看更多信息

3,467

项与哌柏西利相关的文献（医药）

2026-12-31·Journal of Pharmaceutical Policy and Practice

Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis

Article

作者: Hamad, Anas ; Shafei, Laila ; Hisham Al-Ziftawi, Nour ; Mohamed Ibrahim, Mohamed Izham ; Bojassoum, Salha ; Elazzazy, Shereen

Background:

Several trials demonstrated improvements in clinical outcomes associated with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in breast cancer patients. The challenge remains regarding their high costs. Ribociclib and Abemaciclib are cost-effective in Qatar. Yet, their affordability was not studied. This budget impact analysis (BIA) is to assess the affordability of adopting CDK4/6 inhibitors in Qatar over five years duration (2024-2028).

Methods:

We ran a BIA to evaluate two scenarios: (1) Increasing abemaciclib's market share from 20% to 60%, replacing both palbociclib and ribociclib. (2) Assuming equal market share for both ribociclib and abemaciclib up to 80%, reducing palbociclib's share. The analysis considered treatment costs, patient population, and disease prevalence. All data were retrieved from the National Center for Cancer Care and Research, and costs were presented in Qatari Riyals (QAR). Sensitivity analyses were run to ensure the robustness of the conclusion. All results were compared to Qatar's budget threshold, which is QAR 453,822.

Results:

Based on a total of 173 patients using CDK4/6 inhibitors, increasing abemaciclib's market share to 60% yielded cumulative savings of QAR 14 million over five years, which is around QAR 14,613 per patient per year. However, equally increasing ribociclib's and abemaciclib's market share to 80% resulted in a modest budget increase, remaining within acceptable thresholds. Sensitivity analyses confirmed the robustness of these findings, showing that cost reductions and higher uptake rates further enhanced savings.

Conclusion:

Abemaciclib is a budget-saving option for HR+/HER2- breast cancer in Qatar, should it replace the market share by up to 60% over five years. In addition, ribociclib and abemaciclib are affordable treatment options if they equally contributes to up to 80% of the market share for the eligible advanced breast cancer patients. The results supported the concept of allocating CDK4/6 inhibitors as they were found to be affordable to the Qatari healthcare system.

2026-12-01·MOLECULAR BIOLOGY REPORTS

Possible TLR-mediated immunostimulatory effect of Palbociclib in breast cancer

Article

作者: Sağ, Sevda ; Tomatir, Ayse Gaye ; Ergezgin, Huriye ; Bayav, Ibrahim ; Dodurga, Yavuz

BACKGROUND:

Palbociclib, which exerts its effect by inhibiting the cell cycle in cancer cells, is a CDK inhibitor used in the treatment of ER+/HER- breast cancer. In this study, we aimed to investigate the effect of Pablosiklib on TLR, which plays an important role in the immune response, in MCF-7 (ER+/HER2-) and MDA-MB-231 (ER-/PR-/HER2-) cell lines.

METHODS AND RESULTS:

The expression levels of TLR 1-10 genes, cell cycle-related genes (CDK4/6), and genes involved in the apoptotic pathway (Bcl-2, Bax, Cas-3) in MCF-7 and MDA-MB-231 cells treated with palbociclib were evaluated using the real-time PCR (qRT-PCR) method. Additionally, the levels of total retinoblastoma (RB) and phosphorylated retinoblastoma (pRB) proteins were analyzed using the Western blot method. CDK4/6 and pRB expression decreased in MCF-7 and MDA-MB-231 cells treated with palbociclib. Bax and Cas-3 expression increased, while Bcl-2 expression decreased. Changes in TLR expression were also observed.

CONCLUSIONS:

We believe that palbociclib not only stops the cell cycle and induces apoptosis in breast cancer cells, but also activates the immune response via TLRs.

2026-11-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A PROTAC-inspired bifunctional small molecule recruits CDK6 to target EYA2 degradation and suppress breast tumor growth

Article

作者: Qin, Xiaoyu ; Wu, Zhaofeng ; Wang, Yu ; Yuan, Bin ; Kan, Chenchen ; Ma, Junting ; Zhou, Rui ; Liu, Mingming ; Luo, Qichao ; Zhang, Yanhui ; Zhao, Qun ; Gao, Jiahui ; Ai, Jiaxin

Cyclin-dependent kinase 6 (CDK6) has been reported to exert tumor-suppressive functions through its non-enzymatic activity and promotes the degradation of the oncogenic driver EYA2. This suggests a potential strategy for targeted protein degradation by exploiting endogenous protein-protein interactions. Here, we report the design and synthesis of a bifunctional small molecule, EC21, capable of simultaneously engaging CDK6 and EYA2. Structure-guided design based on the reported binding modes of palbociclib and the EYA2 inhibitor ETC-616 enabled the identification of EC21 as a lead compound. Biological studies demonstrated that EC21 effectively reduced EYA2 protein levels in breast cancer cells in a time- and concentration-dependent manner through a ubiquitin-proteasome-dependent process. Mechanistic investigations indicated that EC21 enhances the interaction between CDK6 and EYA2, thereby promoting EYA2 degradation. Functional analyses further revealed that EC21 disrupts DNA damage repair pathways and significantly suppresses breast cancer cell proliferation. Importantly, EC21 exhibited pronounced antitumor activity in a syngeneic breast cancer mouse model and reduced EYA2 protein levels in tumor tissues without apparent toxicity. Collectively, these findings demonstrate that pharmacological stabilization of the CDK6-EYA2 interaction represents a feasible strategy for inducing EYA2 degradation and provides a potential therapeutic approach for EYA2-driven breast cancer.

2,260

项与哌柏西利相关的新闻（医药）

2026-09-01

·GlobeNewswire-Health Care

Celcuity To Participate in Upcoming Investor Conferences

MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Wells Fargo 21st Annual Healthcare Conference at 10:15 a.m. EDT on Tuesday, September 8, 2026. A live webcast will be available using this weblink.A fireside chat at Citi's 2026 Biopharma Back to School Summit at 8:00 a.m. EDT on Wednesday, September 9, 2026. A live webcast will be available using this weblink. Alternatively, the live webcasts will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live events. About Celcuity Celcuity is a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK™ (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- locally advanced or metastatic breast cancer (“ABC”), supported FDA approval of REVTORPYK for use in patients without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of VIKTORIA-1 have been released. VIKTORIA-2 is an ongoing Phase 3 clinical trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib plus palbociclib plus fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib plus palbociclib plus letrozole as first-line treatment for patients with endocrine- sensitive HR+/HER2- ABC. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X. Contacts: Celcuity Inc. Brian Sullivan, bsullivan@celcuity.comVicky Hahne, vhahne@celcuity.com (763) 392-0123 Jodi Sievers, jsievers@celcuity.com(415) 494-9924

临床3期上市批准

2026-09-01

·PRNewswire

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expected By Year-End 2026 and Full Enrollment by End of 2027 SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced new preclinical data demonstrating the safety and anti-tumor activity of paxalisib in HR+/HER2- breast cancer, including evidence that paxalisib resensitized CDK4/6 inhibitor-resistant tumors to standard-of-care therapy. Based on these findings, the Company is moving rapidly to expand its ongoing TNBC clinical trial into hormone receptor-positive ("HR+"), HER2-negative ("HER2-") advanced breast cancer to evaluate this effect directly and filed a related provisional patent application. "HR+/HER2- breast cancer accounts for approximately 60–70% of all breast cancer diagnoses, and we expect nearly 322,000 new cases in the U.S. alone this year," said Dr. John Friend, Chief Executive Officer of Kazia Therapeutics. "That scale, combined with the persistent need for better options once patients progress on standard therapy, represents a significant area of unmet medical need where paxalisib may play a role. Our preclinical data showing statistically significant, additive antitumor activity when paxalisib is combined with standard-of-care therapy gives us strong confidence in this approach, and we are moving quickly to bring this combination into the clinic for these patients. With the completion of our recent financing, based on our current plans and projections, we now have the capital in place to fund this program through completion." In addition to these findings, paxalisib in combination with fulvestrant, and paxalisib in combination with fulvestrant and palbociclib, showed consistent safety and resulted in statistically significant reductions in tumor volume across preclinical models. Kazia has filed a patent that is supported by the Company's preclinical findings and has identified a high-risk subset of metastatic HR+/HER2- breast cancer defined by a novel PI3K/mTOR biomarker, with tissue- and blood-based tests associated with poor survival. Extensive benchmarking studies show that paxalisib can resensitize treatment-resistant tumors to combination therapy through a distinct epigenetic mechanism, an effect not observed with gedatolisib, an FDA-approved intravenous PI3K/mTOR inhibitor, indicating a paxalisib-specific effect rather than a class effect. In a HR+ xenograft model, paxalisib in combination with fulvestrant and palbociclib reduced tumor burden without added toxicity and showed primary tumor growth inhibition comparable to gedatolisib in combination with the same regimen. "Our extensive benchmarking shows that paxalisib is differentiated in targeting the PI3K/mTOR–epigenetic resistance axis and importantly, this is not a class effect," said Dr. Sudha Rao, Chief Scientific Officer, Kazia Therapeutics. "Paxalisib's unique attributes are uncovering a broader role for PI3K/mTOR beyond conventional cytoplasmic signalling, with alternative pathways that may drive metastatic disease and resistance. In HR+ breast cancer, we have identified a novel epigenetic PI3K/mTOR biomarker, with both liquid and tissue tests, that is enriched in patients with poor prognosis. This gives us the opportunity to enrich for the patients where this biology matters most and brings precision medicine to HR+ breast cancer." This benchmarking work is ongoing, and Kazia expects to present additional data later this year, including further cellular, molecular and epigenetic characterization of paxalisib relative to other PI3K/mTOR inhibitors. Current development strategies in this setting have primarily focused on sequencing additional lines of endocrine therapy, targeted agents or antibody-drug conjugates after resistance emerges. Kazia's preclinical findings suggest that paxalisib may address resistance mechanisms at an earlier biological level through epigenetic and transcriptional effects that extend beyond conventional PI3K/mTOR pathway inhibition. Alongside its IP filing, Kazia is amending the protocol of its ongoing TNBC clinical trial to add a three-arm expansion evaluating paxalisib in patients with pre-treated HR+/HER2- metastatic breast cancer. Patients will be randomized to one of three arms: paxalisib at 15mg plus fulvestrant (hormone therapy), with CDK4/6 inhibitor palbociclib; paxalisib at 30mg plus fulvestrant, with palbociclib; or a standard-of-care comparator arm of fulvestrant. The primary endpoint is safety and tolerability, with progression-free survival, overall response rate and overall survival as secondary endpoints. The Company expects sites for this expansion to be activated and the first patient enrolled before the end of 2026, with full enrollment anticipated by the end of 2027. Clinical updates are anticipated throughout 2027, with a full readout anticipated in 2028. About Kazia Therapeutics Kazia Therapeutics (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. The Company's lead asset, paxalisib, is an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of over 15 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM AGILE) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. Additionally, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid/rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially first-in-class SETDB1 inhibitor program intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Both programs are currently in preclinical development. For more information, please visit or follow us on X @KaziaTx. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding: the potential therapeutic benefit of paxalisib in HR+/HER2- breast cancer; the significance of preclinical findings, including benchmarking studies relative to other PI3K/mTOR inhibitors; the Company's plan to expand the ongoing TNBC clinical trial into HR+/HER2- advanced breast cancer; the expected timing of site activation, first patient enrollment and full enrollment; anticipated clinical updates and full data readout timelines; the Company's biomarker program and anticipated future disclosures; and the sufficiency of the Company's capital to fund the program. Forward-looking statements are generally identified by words such as "anticipates," "believes," "expects," "intends," "plans," "may," "will," "could," "should," "estimates," "projects," "potential," and similar expressions. These forward-looking statements are based on management's current expectations and assumptions as of the date of this press release and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to: the preliminary and preclinical nature of the data described, which may not predict clinical outcomes in humans; the ability to successfully amend the existing trial protocol and activate new sites; risks associated with the conduct, timing and enrollment of clinical trials; regulatory review and approval processes; reliance on third-party collaborators and trial sites; the Company's ability to obtain, maintain and protect its intellectual property; the Company's future capital needs and ability to fund planned operations; general economic and market conditions; and the Company's ability to maintain compliance with NASDAQ listing requirements. For a more complete discussion of risks and uncertainties, please refer to the Company's filings with the SEC, including the "Risk Factors" section of the Company's most recent Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements are qualified in their entirety by this cautionary statement. SOURCE Kazia Therapeutics Limited 21% more press release views with Request a Demo

快速通道孤儿药免疫疗法临床申请

2026-09-01

·OncoJ Review 学术科研文献导读

乳腺癌靶向治疗最新论文汇总丨2026年8月

OncoJ Review·肿瘤医学文献速览 200+中英文肿瘤专业期刊·每周更新本期共汇总63篇乳腺癌靶向治疗领域研究论文，覆盖HER2靶向治疗（ADC、TKI）、CDK4/6抑制剂、PARP抑制剂、Trop-2 ADC、PI3K/AKT/mTOR通路抑制剂、新型靶向药物等方向，贯穿新辅助/辅助治疗、一线/后线治疗、耐药后策略及新型药物研发全链条。关键临床启示：EA1181/CompassHER2 pCR二次分析显示新辅助THP方案在HER2+/ER-患者中pCR率近三分之二，低HR表达、HER2 IHC 3+及每周紫杉醇是pCR的独立预测因素（Clinical Oncology）；ELEVATE研究证实艾拉司群联合依维莫司在HR+/HER2-晚期乳腺癌中PFS获益，不受ESR1/PIK3CA突变状态影响（Breast Cancer Research）；卵巢储备功能（AMH）可优化HR+/HER2-绝经前患者辅助化疗获益人群筛选（Annals of Oncology）；吡咯替尼联合卡培他滨对比拉帕替尼联合卡培他滨在HER2+ MBC中OS显著延长（Nature Progress Oncology）；达尔西利联合内分泌治疗在真实世界中保持良好活性，脑转移及既往CDK4/6抑制剂经治患者仍有获益（Therapeutic Advances in Medical Oncology）。新型AURKA抑制剂、Nrf2/Keap1靶向化合物、PROTAC等新药研发方向进展迅速。 🌟 一句话精选：HER2+/ER-乳腺癌新辅助THP方案pCR率近三分之二；艾拉司群联合依维莫司为HR+/HER2-经治晚期乳腺癌提供全口服新选择；AMH可精准筛选辅助化疗获益人群；吡咯替尼联合卡培他滨OS显著优于拉帕替尼方案；达尔西利在真实世界中跨线治疗仍有效。 ⏱️ 30秒速览 HER2靶向治疗：新辅助THP方案pCR预测因素明确；伊尼妥单抗+吡咯替尼+化疗真实世界有效；HLX-02联合帕妥珠单抗或吡咯替尼疗效相当 CDK4/6抑制剂：PalomAGE研究证实70岁及以上患者一线哌柏西利可行且耐受性良好；条件生存分析提供随时间更新的预后信息 PARP抑制剂：TSL-1502 II期研究探索gBRCA突变HER2-晚期乳腺癌；PARP1选择性抑制剂临床演变 PI3K/AKT/mTOR：艾拉司群联合依维莫司ESR1/PIK3CA非依赖性获益 Trop-2 ADC：戈沙妥珠单抗+TRAIL激动剂在TNBC中协同致死耐药机制：CDK8/19抑制防止CDK4/6抑制剂适应性耐药；微环境调控内分泌治疗耐药新靶点：AURKA抑制剂、Nrf2/Keap1、P95-HER2、GPR52等一、临床有参考【HER2靶向治疗】1. Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR HER2阳性乳腺癌中紫杉烷类、曲妥珠单抗和帕妥珠单抗治疗的病理学完全缓解（pCR）率及疗效预测因素：EA1181/CompassHER2 pCR的二次分析期刊：Clinical Oncology 发表时间：2026-08-20 链接：http://oncojreview.cn/c68d48 核心发现：新辅助THP方案在HER2+/ER-乳腺癌患者中实现了近三分之二的pCR，在HER2+/ER+患者中为三分之一。低激素受体表达、HER2 IHC 3+状态、每周一次紫杉醇给药以及较高的HER2DX pCR评分是pCR的独立预测因素。 💡 一句话总结：HER2+/ER-乳腺癌新辅助THP方案pCR率近三分之二，预测因素明确。2. Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study 伊尼妥单抗联合吡咯替尼及化疗治疗HER2阳性转移性乳腺癌的真实世界疗效与安全性：一项多中心回顾性研究期刊：Therapeutic Advances in Medical Oncology 发表时间：2026-08-14 链接：http://oncojreview.cn/1a9cde 核心发现：描述性分析IPyC方案在HER2阳性转移性乳腺癌多线治疗中的应用及结局，该方案在真实世界中显示出良好疗效，强调了设计前瞻性研究以评估该方案的必要性。 💡 一句话总结：伊尼妥单抗+吡咯替尼+化疗在HER2+ MBC真实世界中有效。3. Comparison of the efficacy and safety of HLX-02 plus pertuzumab versus HLX-02 plus pyrotinib in neoadjuvant therapy for HER2-positive breast cancer HLX-02联合帕妥珠单抗对比HLX-02联合吡咯替尼在HER2阳性乳腺癌新辅助治疗中的疗效和安全性比较期刊：Therapeutic Advances in Medical Oncology 发表时间：2026-08-20 链接：http://oncojreview.cn/867e1c 核心发现：两种基于HLX-02的新辅助治疗方案在HER2阳性乳腺癌患者中达到pCR方面疗效相当。HLX-02无论是联合帕妥珠单抗还是吡咯替尼，均为可行的新辅助治疗策略。 💡 一句话总结：HLX-02联合帕妥珠单抗或吡咯替尼新辅助治疗疗效相当。4. Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis 吡咯替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2阳性转移性乳腺癌的总生存期：一项单中心汇总分析期刊：Nature Progress Oncology 发表时间：2026-08-07 链接：http://oncojreview.cn/289dde 核心发现：吡咯替尼联合卡培他滨相较于拉帕替尼联合卡培他滨，在HER2阳性转移性乳腺癌患者中与显著更长的总生存期（OS）相关，为吡咯替尼的OS获益提供了支持性证据。 💡 一句话总结：吡咯替尼+卡培他滨较拉帕替尼方案显著延长HER2+ MBC OS。5. Neoadjuvant pyrotinib for HER2 (IHC 2+/FISH+)/HR+ breast cancer with early non-response: a case report and literature review 吡咯替尼新辅助治疗HER2（IHC 2+/FISH+）/HR+早期无应答乳腺癌：一例病例报告并文献复习期刊：MED 发表时间：2026-08-08 链接：http://oncojreview.cn/80ee9e 核心发现：曲妥珠单抗+帕妥珠单抗（HP）联合化疗是HER2阳性局部晚期乳腺癌推荐新辅助方案，约40%患者未能达到tpCR。本病例报告探讨了吡咯替尼在早期无应答患者中的挽救治疗价值。 💡 一句话总结：吡咯替尼可作为HER2阳性乳腺癌HP方案早期无应答者的挽救策略。6. Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer 抗HER2抗体药物偶联物在HER2阳性及HER2低表达转移性乳腺癌中的临床结局与基因组图谱期刊：Therapeutic Advances in Medical Oncology 发表时间：2026-08-22 链接：http://oncojreview.cn/2c3610 核心发现：提供了四种抗HER2 ADC在HER2阳性和HER2低表达MBC中的描述性真实世界数据。MYC扩增与较差预后相关，强调生物标志物驱动策略的必要性。 💡 一句话总结：抗HER2 ADC在HER2+和HER2-low MBC中有效，MYC扩增提示预后不良。7. Favorable Response to Bevacizumab Plus Capecitabine in a HER2-negative Breast Cancer Patient with Recurrent Brain Metastases: A Case Report 贝伐珠单抗联合卡培他滨治疗HER2阴性乳腺癌复发性脑转移的良好疗效：一例病例报告期刊：Cell Reports Medicine 发表时间：2026-08-24 链接：http://oncojreview.cn/dbd4f1 核心发现：贝伐珠单抗联合卡培他滨为HER2阴性、HR阳性乳腺癌脑转移患者提供了有效的治疗选择。 💡 一句话总结：贝伐珠单抗+卡培他滨是HER2-/HR+乳腺癌脑转移的有效选择。【CDK4/6抑制剂】8. Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older - final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study 哌柏西利一线治疗70岁及以上激素受体阳性HER2阴性局部晚期/转移性乳腺癌的真实世界可行性——法国前瞻性非干预性PalomAGE研究内分泌敏感队列的最终结果期刊：Onco 发表时间：2026-08-11 链接：http://oncojreview.cn/f94ce9 核心发现：一线内分泌治疗联合哌柏西利在70岁及以上、内分泌敏感的HR+/HER2-晚期乳腺癌女性中可行、耐受性良好，并能维持健康相关生活质量。G8工具有助于识别需要进一步老年评估的脆弱患者。 💡 一句话总结：70岁及以上HR+/HER2-晚期乳腺癌一线哌柏西利安全可行。9. Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2-metastatic breast cancer 跨越里程碑：HR+/HER2-转移性乳腺癌一线CDK4/6抑制剂治疗后的基于界标的条件生存期刊：Nature Progress Oncology 发表时间：2026-08-07 链接：http://oncojreview.cn/c0577a 核心发现：基于界标的条件生存分析为接受一线CDK4/6抑制剂治疗的HR+/HER2-转移性乳腺癌提供了随时间更新的预后信息。跨越连续的无进展里程碑可识别出获得持久疾病控制的亚组。 💡 一句话总结：条件生存分析提供CDK4/6抑制剂治疗的动态预后信息。10. Dalpiciclib combined with endocrine therapy for patients with HR+/HER2- metastatic breast cancer: a multicenter real-world study 达尔西利联合内分泌治疗用于HR+/HER2-转移性乳腺癌患者：一项多中心真实世界研究期刊：Therapeutic Advances in Medical Oncology 发表时间：2026-08-01 链接：http://oncojreview.cn/969773 核心发现：达尔西利联合内分泌治疗在HR+/HER2- MBC真实世界队列中保持良好临床活性，在脑转移患者及既往CDK4/6抑制剂经治患者中也显示出有前景的活性。 💡 一句话总结：达尔西利+内分泌治疗在真实世界中跨线治疗仍有效。11. CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities 乳腺癌治疗中的CDK4/6抑制剂：机制、耐药与新兴机遇期刊：Molecular Cancer 发表时间：2026-08-06 链接：http://oncojreview.cn/039e67 核心发现：CDK4/6抑制剂联合内分泌治疗已显著改变HR+/HER2-乳腺癌在转移性及高危早期阶段的治疗策略，多项III期试验证实了OS获益。 💡 一句话总结：CDK4/6抑制剂已成为HR+/HER2-乳腺癌治疗基石。12. P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2- Metastatic Breast Cancer in the USA P-VERIFY：美国HR+/HER2-转移性乳腺癌患者接受CDK4/6抑制剂联合芳香化酶抑制剂的真实世界OS与PFS比较期刊：Breast Cancer Research 发表时间：2026-08-06 链接：http://oncojreview.cn/b5d440 核心发现：报告P-VERIFY研究中CDK4/6抑制剂在HR+/HER2- MBC中的真实世界比较有效性数据，填补了头对头RCT数据的空白。 💡 一句话总结：P-VERIFY提供CDK4/6抑制剂真实世界比较数据。【PARP抑制剂】13. Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer PARP抑制剂TSL-1502治疗胚系BRCA突变、HER2阴性局部晚期/转移性乳腺癌的随机II期试验期刊：Nature Progress Oncology 发表时间：2026-08-09 链接：http://oncojreview.cn/40d0bb 核心发现：葡糖醛酸前药策略可能增强靶向特异性并降低PARP抑制剂毒性。在中国28个研究中心开展的随机、开放标签II期研究（NCT05420779）中，对新型PARP抑制剂TSL-1502进行评价。 💡 一句话总结：新型PARP抑制剂TSL-1502在gBRCA突变HER2-晚期乳腺癌中开展II期研究。14. From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors 从双重抑制到精准选择性：新一代PARP1选择性抑制剂在实体瘤中的分子原理与临床演变期刊：Advanced Oncology 发表时间：2026-08-08 链接：http://oncojreview.cn/8e1fa0 核心发现：标准PARP抑制剂（奥拉帕利、卢卡帕利、尼拉帕利、他拉唑帕利）在乳腺癌、卵巢癌、前列腺癌和胰腺癌中显著有效，但PARP1选择性抑制剂有望提高疗效并降低毒性。 💡 一句话总结：新一代PARP1选择性抑制剂有望克服现有PARP抑制剂的局限性。【Trop-2 ADC及其他ADC】15. Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate sacituzumab govitecan and TRAIL agonists in triple negative breast cancer Trop2靶向抗体药物偶联物戈沙妥珠单抗与TRAIL激动剂联合治疗三阴性乳腺癌的协同致死效应期刊：Breast Cancer Research 发表时间：2026-08-14 链接：http://oncojreview.cn/ac81d2 核心发现：SG与TRAIL激动剂联合治疗在体外诱导TNBC细胞协同致死，并在体内抑制肿瘤生长，提示该联合疗法在TNBC中具有潜在的临床获益。 💡 一句话总结：戈沙妥珠单抗+TRAIL激动剂在TNBC中协同致死。16. Progress of Trop-2-targeted antibody-drug conjugates in HER-2-negative breast cancer: a mini-review Trop-2靶向抗体药物偶联物在HER-2阴性乳腺癌中的研究进展：小型综述期刊：Breast Cancer Research 发表时间：2026-08-12 链接：http://oncojreview.cn/a360ea 核心发现：Trop-2是参与肿瘤生长、增殖和转移的跨膜糖蛋白。靶向Trop-2的ADC通过选择性递送提高了疗效并降低了安全性顾虑。 💡 一句话总结：Trop-2 ADC是HER2-乳腺癌的有前景治疗策略。【PI3K/AKT/mTOR通路抑制剂】17. Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE 艾拉司群联合依维莫司治疗雌激素受体阳性、HER2阴性既往经治晚期乳腺癌：ELEVATE研究结果期刊：Breast Cancer Research 发表时间：2026-08-24 链接：http://oncojreview.cn/d68ce7 核心发现：艾拉司群联合依维莫司在临床/基因组亚组中均显示出具有临床意义的PFS获益，且不受ESR1或PIK3CA突变状态影响。艾拉司群有望成为联合方案中的内分泌治疗基础。 💡 一句话总结：艾拉司群+依维莫司为HR+/HER2-经治晚期乳腺癌提供全口服新方案。【卵巢储备指导化疗获益】18. Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER) 卵巢储备作为SWOG S1007（RxPONDER）研究中HR+/HER2-、淋巴结阳性乳腺癌辅助化疗获益的衡量指标期刊：Annals of Oncology 发表时间：2026-08-18 链接：http://oncojreview.cn/80ee76 核心发现：在年龄<55岁的绝经前患者中，基线AMH<10 pg/ml的受试者未从化疗内分泌治疗（CET）中获益。AMH作为CET获益的指标显著优于绝经状态、年龄或其他激素。 💡 一句话总结：AMH可精准筛选HR+/HER2-绝经前辅助化疗获益人群。【其他靶向治疗】19. Favorable Response to Bevacizumab Plus Capecitabine in a HER2-negative Breast Cancer Patient with Recurrent Brain Metastases: A Case Report 贝伐珠单抗联合卡培他滨治疗HER2阴性乳腺癌复发性脑转移的良好疗效：一例病例报告期刊：Cell Reports Medicine 发表时间：2026-08-24 链接：http://oncojreview.cn/dbd4f1 核心发现：贝伐珠单抗联合卡培他滨为HER2阴性、HR阳性乳腺癌脑转移患者提供了有效的治疗选择。 💡 一句话总结：贝伐珠单抗+卡培他滨是HER2-/HR+乳腺癌脑转移的有效选择。20. Cellular variant focal segmental glomerulosclerosis during trastuzumab emtansine treatment in HER2-positive breast cancer: a case report 恩美曲妥珠单抗治疗HER2阳性乳腺癌期间发生细胞型局灶节段性肾小球硬化：一例病例报告期刊：Cancer Biology & Therapy 发表时间：2026-08-18 链接：http://oncojreview.cn/85f281 核心发现：T-DM1广泛用于HER2阳性乳腺癌治疗，但在T-DM1治疗期间出现的肾小球疾病鲜有报道。本报告描述了一例50岁日本女性患者在T-DM1治疗期间发生FSGS。 💡 一句话总结：T-DM1治疗期间需警惕肾小球疾病。21. Phase 2 test of QBS72S for breast cancer leptomeningeal disease QBS72S治疗乳腺癌软脑膜疾病的II期试验期刊：Neuro-Oncology 发表时间：2026-08-07 链接：http://oncojreview.cn/5cba05 核心发现：早期发现支持进一步研究QBS72S作为软脑膜疾病的靶向治疗，以应对转移性乳腺癌领域未满足的需求。 💡 一句话总结：QBS72S是乳腺癌软脑膜疾病的有前景靶向治疗。22. Anthracycline-Free Neoadjuvant Therapy With Nab-Paclitaxel and Carboplatin in Non-Luminal Breast Cancer: A Single-Arm Clinical Trial 不含蒽环类的白蛋白紫杉醇联合卡铂新辅助治疗非管腔型乳腺癌：一项单臂临床试验期刊：International Journal of Cancer 发表时间：2026-08-18 链接：http://oncojreview.cn/7ea2e7 核心发现：无蒽环类方案因心脏毒性较小受到关注。NEOPATH试验评估白蛋白紫杉醇+卡铂在非管腔型乳腺癌（II-III期TNBC或HER2阳性）新辅助治疗中的疗效和安全性。 💡 一句话总结：白蛋白紫杉醇+卡铂是无蒽环类新辅助治疗的选择。23. Exceptional Response of HER2-Positive Breast Cancer to Osimertinib: A Case Report HER2阳性乳腺癌对奥希替尼的超常反应：一例病例报告期刊：Clinical Lung Cancer 发表时间：2026-08-15 链接：http://oncojreview.cn/5233a0 核心发现：一例HER2阳性乳腺癌患者在因同时性EGFR突变肺腺癌接受奥希替尼单药治疗期间，乳腺癌出现持续缓解。提示ERBB通路抑制可能对部分HER2扩增肿瘤有效。 💡 一句话总结：奥希替尼对同时性EGFR突变肺癌合并HER2+乳腺癌有双重疗效。24. Hypoxia fuels JAK/STAT-LIV1 signaling: A promising therapeutic avenue in triple-negative breast cancer 缺氧驱动JAK/STAT-LIV1信号通路：三阴性乳腺癌中有前景的治疗途径期刊：Current Oncology 发表时间：2026-08-15 链接：http://oncojreview.cn/fb9de3 核心发现：缺氧是TNBC肿瘤微环境的标志性特征，激活JAK/STAT-LIV1信号通路促进转移和免疫逃逸。靶向该通路是TNBC治疗新策略。 💡 一句话总结：靶向JAK/STAT-LIV1通路是TNBC有前景的治疗方向。25. Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer RIBOOLARIS试验的理论基础与试验设计：针对临床高危HR+/HER2阴性乳腺癌的新辅助和辅助瑞博西尼联合内分泌治疗的II期试验期刊：Breast Cancer Research 发表时间：2026-08-15 链接：http://oncojreview.cn/5180a4 核心发现：尽管内分泌治疗取得进展，HR+/HER2-早期乳腺癌仍存在复发风险。化疗常用于高危患者，但并非所有患者均能获益。RIBOOLARIS试验探索瑞博西尼联合内分泌治疗的围术期策略。 💡 一句话总结：RIBOOLARIS试验探索瑞博西尼在HR+/HER2-高危早期乳腺癌围术期中的应用。26. Abemaciclib-Associated Psychosis: A Case Report of a Rare Neuropsychiatric Adverse Effect during Breast Cancer Treatment 阿贝西利相关精神病：乳腺癌治疗期间一种罕见神经精神不良反应的病例报告期刊：Breast Cancer Research 发表时间：2026-08-18 链接：http://oncojreview.cn/97425e 核心发现：本病例强调了识别阿贝西利罕见但严重的神经精神不良反应的重要性，以及密切监测和多学科管理的必要性。 💡 一句话总结：阿贝西利可致罕见但严重的精神病性不良反应。【生物标志物/预后】27. MCV-Neutropenia Risk Score and Overall Survival in HR+/HER2- Advanced Breast Cancer: A Multicenter Retrospective Landmark Analysis MCV-中性粒细胞减少风险评分与HR+/HER2-晚期乳腺癌总生存期：一项多中心回顾性里程碑分析期刊：Dove Medical Press 发表时间：2026-08-23 链接：http://oncojreview.cn/51bace 核心发现：较高的MNRS与后续更优的里程碑总生存期独立相关。MNRS可能代表一种利用常规可获得的血液学参数进行早期风险分层的探索性方法。 💡 一句话总结：MNRS是HR+/HER2-晚期乳腺癌的潜在风险分层工具。28. Biomarker testing in advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative breast cancer: expert recommendations 晚期或转移性HR+/HER2-乳腺癌的生物标志物检测：专家建议期刊：Breast Cancer Research 发表时间：2026-08-18 链接：http://oncojreview.cn/1be5d8 核心发现：由来自拉丁美洲、亚太地区、中东地区的14位专家组成的小组，针对当前及未来HR+/HER2- mBC生物标志物检测和诊断工作流程提出建议。 💡 一句话总结：HR+/HER2- mBC生物标志物检测国际专家共识。29. HR+/HER2-乳腺癌PIK3CA基因突变与淋巴结转移及转移负荷的相关性分析 HR+/HER2-乳腺癌PIK3CA基因突变与淋巴结转移及转移负荷的相关性分析期刊：临床与实验病理学杂志发表时间：2026-08-19 链接：http://oncojreview.cn/034206 核心发现：回顾性纳入73例HR+/HER2-浸润性乳腺癌患者，探讨PIK3CA基因突变状态与淋巴结转移发生及转移负荷之间的关系。 💡 一句话总结：PIK3CA突变与HR+/HER2-乳腺癌淋巴结转移负荷相关。30. Assessment of Trophoblast cell surface antigen 2 (Trop-2) expression and its clinical significance in breast cancer: a multi-level analysis of protein and gene expression 乳腺癌中Trop-2表达的评估及其临床意义：蛋白质与基因表达的多层次分析期刊：Nature Progress Oncology 发表时间：2026-08-06 链接：http://oncojreview.cn/77ebc6 核心发现：Trop-2在所有乳腺癌亚型中均可检出，表达水平范围广泛。Trop-2在早期乳腺癌中可能具有潜在的预后意义。 💡 一句话总结：Trop-2在乳腺癌中广泛表达，具有潜在预后意义。二、转化潜力【耐药机制与联合策略】31. CDK8/19 inhibition prevents adaptive resistance to CDK4/6 inhibitors in vitro and in vivo CDK8/19抑制可在体外和体内防止对CDK4/6抑制剂的适应性耐药期刊：BMC Cancer 发表时间：2026-08-19 链接：http://oncojreview.cn/ab284c 核心发现：CDK4/6抑制剂耐药性容易产生，限制了对患者生存的影响。CDK8/19 Mediator抑制剂可防止肿瘤细胞对CDK4/6抑制剂的适应性耐药。 💡 一句话总结：CDK8/19抑制是防止CDK4/6抑制剂耐药的潜在策略。32. The tumour microenvironment influences long-term tamoxifen benefit in postmenopausal ER+/HER2- breast cancer patients: a secondary analysis of the randomised Stockholm Tamoxifen (STO-3) trial 肿瘤微环境影响绝经后ER+/HER2-乳腺癌患者他莫昔芬长期获益：随机STO-3试验的二次分析期刊：BMC Cancer 发表时间：2026-08-06 链接：http://oncojreview.cn/41d20a 核心发现：低免疫细胞丰度、中等内皮细胞丰度和低/中等成纤维细胞丰度与他莫昔芬获益改善相关，提示免疫和基质区室均影响内分泌治疗疗效。 💡 一句话总结：肿瘤微环境组成调控他莫昔芬疗效。33. Baicalein targets the Nrf2/Keap1 interaction and related stress pathways to mitigate drug-induced toxicity and reverse resistance in breast cancer: A review 黄芩素靶向Nrf2/Keap1相互作用及相关应激通路，以减轻乳腺癌中药物诱导的毒性并逆转耐药期刊：Cancer Cell 发表时间：2026-08-15 链接：http://oncojreview.cn/9926d1 核心发现：Nrf2/Keap1在乳腺癌各亚型中经常发生失调，既可驱动细胞保护也可驱动细胞死亡。天然黄酮类化合物黄芩素（BAI）因靶向该通路而具有治疗潜力。 💡 一句话总结：黄芩素靶向Nrf2/Keap1，有潜力逆转耐药并减轻毒性。【新型靶点与药物发现】34. Discovery of Novel AURKA Inhibitors for Triple-Negative Breast Cancer (TNBC) Therapy via a Hybrid Virtual Screening Pipeline, Biological Evaluation and Molecular Dynamics Simulation 通过混合虚拟筛选发现用于三阴性乳腺癌治疗的新型AURKA抑制剂期刊：Cancer Cell 发表时间：2026-08-08 链接：http://oncojreview.cn/38e895 核心发现：AURKA是TNBC恶性进展和预后不良的关键驱动因素。开发了级联式AI驱动的虚拟筛选流程，从16万种化合物库中发现新型AURKA抑制剂候选物。 💡 一句话总结：AI驱动虚拟筛选发现新型AURKA抑制剂用于TNBC治疗。35. P95-HER2 promotes metastatic progression by biasing MRTFA dependent signaling P95-HER2通过偏向MRTFA依赖性信号传导促进转移进展期刊：Cancer Cell 发表时间：2026-08-01 链接：http://oncojreview.cn/34aa3e 核心发现：HER2的N端截短亚型（p95）在检出前更倾向于早期远处播散。p95-HER2通过偏向性利用酪氨酸信号差异化地促进“迁移或增殖”表型。 💡 一句话总结：p95-HER2是促进乳腺癌早期转移的关键亚型。36. Role of orphan G protein-coupled receptor GPR52 in breast cancer cell multicellular organization and collective invasion 孤儿G蛋白偶联受体GPR52在乳腺癌细胞多细胞组织化与集体侵袭中的作用期刊：British Journal of Cancer 发表时间：2026-08-20 链接：http://oncojreview.cn/59094f 核心发现：GPR52缺失是乳腺癌进展的一种潜在机制，支持探索GPR52激动作用作为乳腺癌的治疗选择。 💡 一句话总结：GPR52是乳腺癌的潜在治疗靶点。37. Magnolol triggers ferroptosis in triple-negative breast cancer through modulation of the ETS2/SLC7A11/GPX4 signaling axis 厚朴酚通过调控ETS2/SLC7A11/GPX4信号轴触发三阴性乳腺癌铁死亡期刊：Breast Cancer Research 发表时间：2026-08-15 链接：http://oncojreview.cn/937ffe 核心发现：厚朴酚诱导MDA-MB-231细胞发生铁死亡，机制涉及靶向ETS2/SLC7A11/GPX4信号轴。 💡 一句话总结：厚朴酚通过铁死亡通路发挥抗TNBC活性。38. Glycoconjugate strategy for GLUT-driven curcumin delivery and anticancer activity in breast cancer cells 基于糖缀合物策略的GLUT驱动姜黄素递送及其在乳腺癌细胞中的抗癌活性期刊：Modern Pathology 发表时间：2026-08-14 链接：http://oncojreview.cn/331e7b 核心发现：利用恶性肿瘤细胞中GLUTs的过表达，开发了糖缀合物氧钒配合物作为GLUT导向的抗乳腺癌抗癌剂。 💡 一句话总结：糖缀合物策略实现GLUT驱动的姜黄素靶向递送。39. Inducing Metabolic Dysfunction in Breast Cancer Cells Through Targeted Inhibition of α- and β-Glucosidase and Amylase: Novel Carbohydrate (C₈N) Isomers 通过靶向抑制葡萄糖苷酶及淀粉酶诱导乳腺癌细胞代谢功能障碍：新型C₈N异构体期刊：Cancer Cell / Molecular Cell 发表时间：2026-08-15 链接：http://oncojreview.cn/887d1c 核心发现：基于氨基环醇的新型葡萄糖苷酶抑制剂通过新方法合成，可诱导乳腺癌细胞代谢功能障碍。 💡 一句话总结：新型葡萄糖苷酶抑制剂通过代谢靶向抑制乳腺癌。40. In silico and In vitro studies of EGFR kinase and Anilide derivatives as inhibitors against Breast Cancer EGFR激酶与酰苯胺衍生物作为乳腺癌抑制剂的计算机模拟和体外研究期刊：Blood Cancer Journal 发表时间：2026-08-15 链接：http://oncojreview.cn/6429f8 核心发现：以厄洛替尼为参照，通过分子对接设计具有卤素取代的苯甲酰苯胺类化合物，针对EGFR激酶进行筛选。 💡 一句话总结：新型苯甲酰苯胺衍生物是潜在的EGFR靶向乳腺癌抑制剂。【靶向治疗相关预后/生物标志物】41. Comprehensive Analysis of m6A Regulators Identifies YTHDF3 as a Promising Prognostic Biomarker for Breast Cancer m6A调节因子的综合分析确定YTHDF3是乳腺癌中有前景的预后生物标志物期刊：Clinical Oncology 发表时间：2026-08-18 链接：http://oncojreview.cn/cac1ba 核心发现：利用多组学数据集和实验验证，发现YTHDF3在乳腺癌中显著差异表达，可能作为预后生物标志物。 💡 一句话总结：YTHDF3是乳腺癌的潜在预后生物标志物。42. Proteomic Biomarker Discovery in Breast Cancer: Advances, Challenges, and Translational Prospects 乳腺癌蛋白质组学生物标志物发现：进展、挑战与转化前景期刊：Cancer Biology & Therapy 发表时间：2026-08-10 链接：http://oncojreview.cn/ac3340 核心发现：尽管在基因组分类和靶向治疗方面取得重大进展，识别临床可靠的蛋白质组学标志物用于早期检测、预后分层和治疗反应预测仍是转化难题。 💡 一句话总结：蛋白质组学标志物发现是乳腺癌精准治疗的关键挑战。43. Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel Assay 年龄与复发/难治性癌症肿瘤基因组特征的关联期刊：Molecular Cancer Therapeutics 发表时间：2026-08-07 链接：http://oncojreview.cn/f323ba 核心发现：在复发/难治性疾病中，CCND1扩增在AYA乳腺癌中更为常见，提示年龄相关的基因组差异可能影响靶向治疗策略。 💡 一句话总结：年龄影响复发/难治性乳腺癌的基因组特征。44. Assessment of Trophoblast cell surface antigen 2 (Trop-2) expression and its clinical significance in breast cancer: a multi-level analysis of protein and gene expression 乳腺癌中Trop-2表达的评估及其临床意义：蛋白质与基因表达的多层次分析期刊：Nature Progress Oncology 发表时间：2026-08-06 链接：http://oncojreview.cn/77ebc6 核心发现：Trop-2在所有乳腺癌亚型中均可检出，表达水平范围广泛。Trop-2在早期乳腺癌中可能具有潜在的预后意义。 💡 一句话总结：Trop-2是乳腺癌有前景的生物标志物和治疗靶点。【新药递送系统】45. TRAIL PLGA/Gelucire 48/16 and exosome carrier systems enhance anti-tumor efficacy by enabling autophagic motility TRAIL PLGA/Gelucire 48/16及外泌体载体系统通过赋予自噬运动能力增强抗肿瘤疗效期刊：Molecular Cancer Therapeutics 发表时间：2026-08-05 链接：http://oncojreview.cn/90a607 核心发现：开发了新型负载TRAIL的药物载体系统，以延长其半衰期并增强生物活性，在体外和体内评估了其肿瘤靶向性及对凋亡和自噬通路的调控。 💡 一句话总结：新型TRAIL递送系统增强抗乳腺癌疗效。46. Highly Efficient Homologous Targeting Magnetic Resonance Imaging Probe for Enhanced T1 Contrast Imaging of Triple-Negative Breast Cancer 基于灭活肿瘤细胞负载碳酸锰的高效同源靶向MRI探针用于三阴性乳腺癌增强T1对比成像期刊：Blood Cancer Journal 发表时间：2026-08-18 链接：http://oncojreview.cn/1160a6 核心发现：开发了具有pH响应特性的同源靶向T1 MRI探针（灭活4T1细胞负载MnCO₃纳米簇），用于TNBC精准诊断。 💡 一句话总结：新型同源靶向MRI探针实现TNBC精准诊断。三、基础研究【信号通路与分子机制】47. DARS2 Promotes Tumorigenesis and Metastasis by Activating PI3K/Akt/GSK-3β/β-Catenin Signaling Pathway in Breast Cancer DARS2通过激活PI3K/Akt/GSK-3β/β-Catenin信号通路促进乳腺癌的肿瘤发生和转移期刊：Breast Cancer Research 发表时间：2026-08-07 链接：http://oncojreview.cn/393732 核心发现：DARS2是负责天冬氨酰-tRNA氨酰化的线粒体酶，在乳腺癌中通过激活PI3K/Akt/GSK-3β/β-Catenin通路促进肿瘤发生和转移。 💡 一句话总结：DARS2是乳腺癌肿瘤发生和转移的潜在驱动因子。48. Investigating POLG-driven modulation of cancer stemness: a pilot study in breast cancer cells 探究POLG驱动的肿瘤干性调控：一项在乳腺癌细胞中的初步研究期刊：Breast Cancer Research 发表时间：2026-08-10 链接：http://oncojreview.cn/82066a 核心发现：线粒体已成为乳腺癌干细胞（CSC）生物学的重要调控因子。靶向线粒体DNA聚合酶γ（POLG）可能削弱CSC维持。 💡 一句话总结：POLG是乳腺癌干细胞干性维持的潜在靶点。49. Metastasis of triple negative breast cancer is regulated by a targetable miR-342-E2F network 三阴性乳腺癌的转移受可靶向的miR-342-E2F网络调控期刊：Breast Cancer Research 发表时间：2026-08-21 链接：http://oncojreview.cn/eeeb2b 核心发现：miR-342是TNBC转移的抑制因子。在免疫健全和异种移植TNBC模型中，miR-342的时序性再表达显著抑制转移进展。 💡 一句话总结：miR-342-E2F网络是TNBC转移的可靶向调控轴。50. miR-640 Enhances Abemaciclib Sensitivity by Suppressing CDK Inhibitor Resistance-Associated Genes in Breast Cancer Cells miR-640通过抑制乳腺癌细胞中CDK抑制剂耐药相关基因增强阿贝西利敏感性期刊：Cancer Biology & Therapy 发表时间：2026-08-10 链接：http://oncojreview.cn/ba8e0c 核心发现：miR-640可下调CDK4/6抑制剂耐药相关基因，单独及联合abemaciclib在乳腺癌细胞中具有促凋亡、抗转移和抗增殖作用。 💡 一句话总结：miR-640是增强阿贝西利敏感性的潜在靶点。51. Quercetin inhibits breast cancer progression by inducing ferroptosis via the NEDD4L-SLC7A11 axis 槲皮素通过NEDD4L-SLC7A11轴诱导铁死亡抑制乳腺癌进展期刊：Cancer Biology & Therapy 发表时间：2026-08-12 链接：http://oncojreview.cn/df3f88 核心发现：槲皮素能显著抑制乳腺癌细胞的活力、增殖和迁移能力，机制涉及NEDD4L-SLC7A11轴介导的铁死亡。 💡 一句话总结：槲皮素通过铁死亡通路抑制乳腺癌进展。52. The estrogen-integrin αvβ3 crosstalk in breast cancer: Modulating PD-L1 and immune evasion 乳腺癌中雌激素-整合素αvβ3的交互作用：调控PD-L1与免疫逃逸期刊：Breast Cancer Research 发表时间：2026-08-04 链接：http://oncojreview.cn/49a637 核心发现：提出“双轨”调节模型：ER-α介导的基因组信号抑制PD-L1转录，而整合素αvβ3介导的非基因组信号通过激活PI3K/Akt与MAPK/ERK通路驱动PD-L1呈递。 💡 一句话总结：雌激素通过基因组和非基因组“双轨”调控PD-L1。53. The chemokine network in triple-negative breast cancer: its role in immune microenvironment regulation, and prospects for targeted therapy 三阴性乳腺癌中的趋化因子网络：在免疫微环境调控中的作用及靶向治疗前景期刊：Nature Progress Oncology 发表时间：2026-08-20 链接：http://oncojreview.cn/1d1db2 核心发现：趋化因子网络是TNBC肿瘤免疫微环境（TIME）的核心协调者，决定治疗应答性。系统整合了趋化因子网络调控TIME的现有证据。 💡 一句话总结：趋化因子网络是TNBC免疫微环境和靶向治疗的关键调控枢纽。54. Emerging therapeutic strategies for triple-negative breast cancer using ruthenium, iridium, and rhenium complexes 基于钌、铱和铼配合物的三阴性乳腺癌新兴治疗策略期刊：Cancer Cell 发表时间：2026-08-20 链接：http://oncojreview.cn/8c12d5 核心发现：总结了近年来使用钌、铱和铼配合物作为TNBC替代治疗药物的进展。这些金属配合物通过响应肿瘤特异性生物标志物或TME实现选择性摄取。 💡 一句话总结：金属配合物是TNBC有前景的新型靶向治疗策略。55. Metabolomics-Driven Bioactivity-Guided Isolation and Molecular Docking Reveal Antibreast Cancer Metabolome Heterogeneity in Polygonum spp 代谢组学驱动的生物活性导向分离揭示蓼属植物抗乳腺癌代谢组异质性期刊：BMC Cancer 发表时间：2026-08-17 链接：http://oncojreview.cn/46edd1 核心发现：拳参和珠芽蓼的代谢组指纹图谱与TNBC抑制活性相关，共注释209种代谢物，其中黄酮类为主要类别。 💡 一句话总结：蓼属植物代谢组具有抗TNBC活性异质性。56. Anticancer activity of lichen-derived compounds against triple-negative breast cancer: integrated in vitro evaluation, network pharmacology, molecular docking, and KEGG pathway analysis 地衣来源化合物抗三阴性乳腺癌活性：体外评价、网络药理学、分子对接及KEGG通路分析的综合研究期刊：Breast Cancer Research 发表时间：2026-08-15 链接：http://oncojreview.cn/c3257f 核心发现：采用体外实验与计算机模拟相结合的综合方法，探讨了六种地衣来源化合物对MDA-MB-231细胞的抗癌潜力。 💡 一句话总结：地衣来源化合物是TNBC的潜在药物来源。57. Prenylated 4-Hydroxycoumarin derivatives as inducers of CDK4/6-mediated cell cycle arrest: From design and synthesis to in vitro and in vivo evaluation 异戊二烯基化4-羟基香豆素衍生物作为CDK4/6介导的细胞周期阻滞诱导剂期刊：Molecular Cancer Therapeutics 发表时间：2026-08-09 链接：http://oncojreview.cn/089176 核心发现：受Ferulin C和Miliusol的异戊烯基香豆素骨架启发，合成了一系列新型4-羟基香豆素衍生物，先导化合物PB1-3对MCF-7细胞展现出最强抗增殖活性（IC₅₀=3.13 μM）。 💡 一句话总结：新型香豆素衍生物通过CDK4/6介导的细胞周期阻滞抑制乳腺癌。58. Mitochondrial Mediated Apoptosis Evaluation of Myristicin on Triple Negative Breast Cancer Model Via Bcl2/Bid Pathway 肉豆蔻醚通过Bcl2/Bid通路对三阴性乳腺癌模型线粒体介导凋亡的评估期刊：Signal Transduction and Targeted Therapy 发表时间：2026-08-11 链接：http://oncojreview.cn/7c59f5 核心发现：肉豆蔻醚是一种具有抗癌特性的活性芳香族化合物，在TNBC细胞上通过Bcl2/Bid通路诱导线粒体介导的凋亡。 💡 一句话总结：肉豆蔻醚通过线粒体凋亡通路发挥抗TNBC活性。59. HSPA8 globally modulates transcriptome profile and PI3K/AKT signaling pathway to facilitate malignant progression phenotypes of triple-negative breast cancer HSPA8全局调控转录组谱及PI3K/AKT信号通路促进三阴性乳腺癌恶性进展期刊：Cancer Cell 发表时间：2026-08-20 链接：http://oncojreview.cn/54aa47 核心发现：HSPA8是参与多种癌症相关蛋白正确折叠或降解的伴侣蛋白，在TNBC中通过调控转录组和PI3K/AKT通路促进恶性进展。 💡 一句话总结：HSPA8是TNBC恶性进展的关键调控因子。四、交叉领域60. Breaking barriers: nanosystems to overcome solubility and permeability challenges of second-generation tyrosine kinase inhibitors 突破障碍：纳米系统克服第二代酪氨酸激酶抑制剂的溶解度与渗透性挑战期刊：Breast Cancer Research 发表时间：2026-08-18 链接：http://oncojreview.cn/0aacbd 核心发现：第二代TKIs（博舒替尼、尼洛替尼、达沙替尼）在多种恶性肿瘤中显示疗效，但属II/IV类药物，溶解性和渗透性差。纳米系统为克服此挑战提供策略。 💡 一句话总结：纳米递送系统可改善第二代TKI在乳腺癌中的生物利用度。61. AI-driven CRISPR strategies in breast cancer: Organoid modeling, adaptive editing, and precision delivery 乳腺癌中AI驱动的CRISPR策略：类器官建模、自适应编辑与精准递送期刊：Breast Cancer Research 发表时间：2026-08-18 链接：http://oncojreview.cn/53c75c 核心发现：CRISPR-Cas9正超越单纯基因编辑工具，能够恢复昼夜节律完整性、清除休眠克隆并重编程免疫监视，为靶向治疗提供新平台。 💡 一句话总结：AI驱动的CRISPR策略为乳腺癌精准靶向治疗提供新工具。62. Food packaging-derived endocrine disruptors and breast cancer nutrition: dietary exposure, estrogen signaling, and survivorship implications 食品包装来源的内分泌干扰物与乳腺癌营养：膳食暴露、雌激素信号传导及生存期影响期刊：Breast Cancer Research 发表时间：2026-08-20 链接：http://oncojreview.cn/f593b9 核心发现：食品包装中的内分泌干扰物（双酚类、邻苯二甲酸酯类、PFAS）可通过靶向雌激素信号通路影响乳腺癌风险。 💡 一句话总结：食品包装内分泌干扰物是乳腺癌的潜在环境风险因素。63. Lung Cancer Patient Advocacy Progress and New Challenges Since 2006 自2006年以来肺癌患者倡导的进展与新挑战期刊：Clinical Cancer Research 发表时间：2026-08-04 链接：http://oncojreview.cn/09261b 核心发现：在过去二十年中，靶向治疗、免疫治疗、分子诊断方面的变革性进展已极大地改变了癌症治疗格局。靶向治疗是其中的关键驱动力之一。 💡 一句话总结：靶向治疗是过去二十年癌症治疗变革的重要组成。 📌内容说明内容基于近200种中英文期刊的论文筛选阅读原文，推荐在浏览器访问[原文链接] 以上内容仅供参考，不构成临床诊疗建议英文的中文翻译仅供参考，请以原文为准 📚推荐阅读查询更多医学专业图书，点击文末[阅读原文]进入[肿瘤医生书友汇] 扫码关注 OncoJ Review 学术科研文献导读

100 项与哌柏西利相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10372	哌柏西利	L01XE33	DB09073

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
HR阳性/HER2阳性乳腺癌	美国	Pfizer Inc.	2026-06-24
复发性乳腺癌	日本	Pfizer Japan, Inc.	2017-09-27
HR阳性/HER2阴性乳腺癌	美国	Pfizer Inc.	2016-02-19
ER阳性/HER2阴性乳腺癌	美国	Pfizer Inc.	2015-02-03

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HPV相关鳞状细胞癌	临床3期	美国	Pfizer Inc.	2022-04-06
头颈部鳞状细胞癌	临床3期	美国	Pfizer Inc.	2022-04-06
转移性头颈部鳞状细胞癌	临床3期	美国	Pfizer Inc.	2022-04-06
HR阳性HER2阴性淋巴结阳性乳腺癌	临床3期	奥地利	Pfizer Inc.	2019-08-27
HR阳性HER2阴性淋巴结阳性乳腺癌	临床3期	法国	Pfizer Inc.	2019-08-27
HR阳性HER2阴性淋巴结阳性乳腺癌	临床3期	匈牙利	Pfizer Inc.	2019-08-27
HR阳性HER2阴性淋巴结阳性乳腺癌	临床3期	意大利	Pfizer Inc.	2019-08-27
HR阳性HER2阴性淋巴结阳性乳腺癌	临床3期	西班牙	Pfizer Inc.	2019-08-27
HR阳性HER2阴性淋巴结阳性乳腺癌	临床3期	瑞士	Pfizer Inc.	2019-08-27
HER2 阴性乳腺癌	临床3期	日本	Pfizer Inc.	2019-07-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03423199 (PATHWAY, Pubmed \| Breast Cancer)	临床3期	HR阳性/HER2阴性乳腺癌 HR+ \| HER2-	328	Palbociclib plus Tamoxifen	鹹鏇鹹鏇願壓獵範積製(蓋齋膚積觸鏇淵繭鏇鹽) = cycle 4: 0.70 [95% CI: -5.00, 6.41]; cycle 7: 2.17 [95% CI: -4.14, 8.48]; EOT: -5.19 [95% CI: -11.64, 1.26] 繭餘繭淵膚網壓艱鏇糧 (簾繭憲遞衊繭壓壓構鏇 ) 更多	积极	2026-06-24
				Placebo plus Tamoxifen
ESMO_GCC2026	临床2期	转移性子宫内膜恶性肿瘤 estrogen receptor-positive	29	Palbociclib and anastrozole	繭網鬱鹽範壓鏇夢餘簾(淵夢網夢憲願糧製顧積) = 範窪願憲衊淵獵齋糧壓衊構蓋遞廠築襯艱願糧 (餘繭構膚鹽顧鑰製鏇繭 ) 更多	积极	2026-06-18
NCT04767594 (PERFORM, ASCO2026)	N/A	HR阳性/HER2阴性乳腺癌一线 HR+/HER2−	1,010	Palbociclib + ET (TFI >12 months)	顧鑰鹹衊蓋鏇醖憲蓋簾(繭衊淵襯簾膚壓遞鹹遞) = 壓願襯繭鹹淵鹹壓顧鹽淵夢窪糧廠範淵憲夢簾 (顧遞衊願鏇襯範餘鑰窪, 23.3 ~ 33.1) 更多	积极	2026-05-29
				Palbociclib + ET (TFI ≤12 months)	顧鑰鹹衊蓋鏇醖憲蓋簾(繭衊淵襯簾膚壓遞鹹遞) = 積製鏇膚艱衊衊窪遞膚淵夢窪糧廠範淵憲夢簾 (顧遞衊願鏇襯範餘鑰窪, 9.3 ~ 19.4) 更多
NCT03079011 (PADA-1, ASCO2026)	临床2期	ER阳性/HER2阳性乳腺癌一线 ER+/HER2-	45	AI+palbociclib	選遞廠簾襯衊憲繭鏇襯(蓋繭願衊衊願襯獵顧範) = 壓積襯蓋襯獵範憲鑰糧蓋憲淵獵築鹽艱壓淵鹽 (壓襯鑰築餘構蓋襯遞廠 ) 更多	积极	2026-05-29
ASCO2026	N/A	HR阳性/HER2阴性乳腺癌 HR+ \| HER2-	5,472	Ribociclib	窪鏇衊憲網製壓餘遞遞(鑰願鏇糧膚獵壓衊齋艱): HR = 0.65 (95.0% CI, 0.552 ~ 0.758), P-Value = <0.0001 更多	积极	2026-05-29
				Palbociclib (HR+/HER2- metastatic breast cancer)
ASCO2026	N/A	转移性HER2阴性乳腺癌 HR-positive \| HER2-negative	97	Generic Palbociclib + Endocrine Therapy	鑰鑰襯夢繭範願構積淵(憲醖製鏇積鬱齋憲醖糧) = 壓製築憲鑰製醖醖衊鑰糧繭願顧範廠願製齋襯 (選範繭憲鏇蓋鏇襯壓衊, 80.1 ~ 94.5) 更多	积极	2026-05-29
NCT03423199 (PATHWAY, ASCO2026)	临床3期	HR阳性/HER2阴性乳腺癌二线 \| 一线 HR-positive \| HER2-negative	184	Palbociclib + Tamoxifen ± Goserelin	艱選鏇衊糧鹽廠糧願夢(製襯鹽憲獵淵觸艱鑰鑰) = 餘遞遞選壓蓋夢艱構壓遞簾鹹鹽鹹鑰淵醖選鹹 (艱蓋餘夢壓選醖構製襯, 13.1 ~ 32.4) 更多	积极	2026-05-29
				Placebo + Tamoxifen ± Goserelin	艱選鏇衊糧鹽廠糧願夢(製襯鹽憲獵淵觸艱鑰鑰) = 憲餘鹽選淵繭餘顧膚願遞簾鹹鹽鹹鑰淵醖選鹹 (艱蓋餘夢壓選醖構製襯, 7.4 ~ 14.6) 更多
NCT06495164 (Pubmed \| Oncologist)	N/A	转移性乳腺癌一线 HR Positive \| HER2 Negative	11,557	Palbociclib + AI	鹹夢衊積範積築構夢構(醖製積鏇製選願製範憲) = 簾餘網觸築鏇廠蓋鹽遞蓋範蓋築願繭醖繭獵鹹 (夢廠憲網衊願願鑰觸衊 ) 更多	积极	2026-05-08
				Ribociclib + AI	鹹夢衊積範積築構夢構(醖製積鏇製選願製範憲) = 鏇鏇憲蓋簾醖觸齋齋衊蓋範蓋築願繭醖繭獵鹹 (夢廠憲網衊願願鑰觸衊 ) 更多
EUCTR2016-002893-11-SE (PASIPHAE, ESMO_BC2026)	临床2期	HR阳性/HER2阴性乳腺癌一线 HR+/HER2-	41	Capecitabine	簾選繭範餘顧鹹繭願選(繭鹽觸觸艱觸鏇憲選構) = 鑰鏇獵簾淵廠襯夢廠餘憲醖觸鏇築艱窪醖膚窪 (膚選鹹鑰網蓋顧選廠艱 ) 更多	积极	2026-05-07
				Fulvestrant/ Palbociclib	簾選繭範餘顧鹹繭願選(繭鹽觸觸艱觸鏇憲選構) = 積遞鹹窪範膚願糧淵網憲醖觸鏇築艱窪醖膚窪 (膚選鹹鑰網蓋顧選廠艱 ) 更多
ESMO_BC2026	N/A	转移性乳腺癌一线 HR+/HER2−	142	Palbociclib + Palbociclibherapy	醖襯艱襯蓋獵築壓簾夢(鑰顧淵膚選構製鹽鏇觸) = 鹹衊遞淵夢顧網糧壓鹽艱蓋鑰窪憲鏇願醖鏇選 (獵壓糧鬱餘膚窪製艱鹹 ) 更多	积极	2026-05-07
				Ribociclib + Ribociclibtherapy	顧齋糧顧夢鹽壓鹹鏇淵(憲遞餘糧簾蓋選醖顧壓) = 選網鹽製製顧艱衊獵膚壓製獵壓醖網築衊醖襯 (膚網願壓積築選網鹹築 )